Since the beginning of the vaccination campaign against the Covid they arrived at Aifa 91,360 reports of suspected adverse reaction out of a total of 76,509,846 doses administered (rate of 119 every 100 thousand doses). Of these, only 13.8% were serious reports, with a rate of 13 serious events every 100 thousand inoculations. L’86,1% of the reports refer to reports such as pain at the injection site, fever, asthenia / fatigue, muscle aches. These are the data that emerge from the eighth report of Pharmacovigilance on the 4 covid vaccines developed by the Italian Medicines Agency.
The same Aifa, with an opinion from its technical-scientific commission, also reports i dangers related to the use of the drug Parvulan, indicated for the treatment ofHerpes Zoster, illegal in Italy, but used by some in sostitution of the anti-Covid vaccine. L’alert was triggered following the increase in suspicious requests for Parvulan imports. The drug, used for the so-called shingles, is not authorized. “The use of the drug in the prophylaxis of Sars-CoV-2”, explains the opinion, “is not supported by the slightest evidence of effectiveness e safety“And is” a potential danger for people’s health “.
The pharmacovigilance report
As already reported in previous pharmacovigilance reports on the 4 covid vaccines, regardless of vaccine, dose and type of event, the reaction occurred in the majority of cases (80% about) in same day vaccination or the next day. Only more rarely beyond the following 48 hours. Comirnaty is the vaccine currently most used in the Italian vaccination campaign (71%), followed by Vaxzevria (16%), Spikevax (11%) e Janssen (2%). The distribution of reports by type of vaccine is similar to that of administrations (Comirnaty 67%, Vaxzevria 24%, Spikevax 8%, Janssen 1%). For all vaccines, the most reported adverse events are fever, fatigue, headache, muscle / joint pain, local reaction or pain at the injection site, chills and nausea.
In relation to the so-called vaccinations heterologous people under 60 who had received Vaxzevria as their first dose have been received 248 records found, out of a total of 604,865 administrations (the second dose concerned in 76% of the Comirnaty cases and in 24% Spikevax), with a reporting rate of 41 every 100 thousand doses administered.
In the age range between 12 and 19 years, have been received 838 records of suspected adverse event out of a total of 3,798,938 doses of Covid vaccine administered, with a reporting rate of 22 adverse events every 100 thousand doses administered. There distribution by type of adverse events it is not substantially different from that observed for all other age groups.